Wecome Pharmaceutical Co Ltd
Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of modern traditional Chinese and western medicine in China. The company offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. It also operates the retail of pharmaceutical commercial products. The company was formerly k… Read more
Wecome Pharmaceutical Co Ltd (300878) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.001x
Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) has a cash flow conversion efficiency ratio of -0.001x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-1.42 Million) by net assets (CN¥1.03 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wecome Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Wecome Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Wecome Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wecome Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DOUGLAS ELLIMAN DL-01
F:8OT
|
N/A |
|
Ginebra San Miguel Inc
PINK:GBSMF
|
0.001x |
|
Jiangsu Teeyer Intelligent Equipment Co.,Ltd.
SHG:603273
|
-0.011x |
|
CAMP4 THERAPEUTICS CORPORATION
NASDAQ:CAMP
|
0.132x |
|
GENERALFINANCE SPA
F:VG30
|
N/A |
|
iHeartMedia Inc
PINK:IHRTB
|
-0.023x |
|
AGIOE ORD A (SHH) EQSW Exp:
SHG:688450
|
N/A |
|
Power Metallic Mines Inc.
F:IVV1
|
-0.844x |
Annual Cash Flow Conversion Efficiency for Wecome Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Wecome Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.17 Billion | CN¥-27.17 Million | -0.023x | -155.89% |
| 2023-12-31 | CN¥1.41 Billion | CN¥58.29 Million | 0.041x | -60.11% |
| 2022-12-31 | CN¥1.41 Billion | CN¥146.57 Million | 0.104x | +315.97% |
| 2021-12-31 | CN¥1.41 Billion | CN¥-67.74 Million | -0.048x | -255.47% |
| 2020-12-31 | CN¥1.38 Billion | CN¥42.81 Million | 0.031x | -85.74% |
| 2019-12-31 | CN¥519.84 Million | CN¥112.76 Million | 0.217x | -19.08% |
| 2018-12-31 | CN¥393.83 Million | CN¥105.57 Million | 0.268x | +182.87% |
| 2017-12-31 | CN¥306.05 Million | CN¥29.00 Million | 0.095x | -80.04% |
| 2016-12-31 | CN¥210.90 Million | CN¥100.15 Million | 0.475x | +108.41% |
| 2015-12-31 | CN¥130.04 Million | CN¥29.63 Million | 0.228x | -61.26% |
| 2014-12-31 | CN¥78.22 Million | CN¥46.01 Million | 0.588x | -22.24% |
| 2013-12-31 | CN¥34.35 Million | CN¥25.98 Million | 0.756x | -- |